Cambridge Healthtech Institute’s Inaugural

Small G Proteins

Targeting Ras, Other Small GTPases and Their Molecular Partners

September 16-17, 2020


Small G proteins are a superfamily of intracellular enzymes with similar core structures that hydrolyze GTP molecules and play roles important to cell growth and other core cellular processes. The most ‘famous’ small G protein subfamily, Ras proteins, has been known for decades to contribute to the growth of many types of cancerous cells when Ras is stuck in its ‘ON’, GTP-bound state. Yet, drug discovery efforts to find small molecule drugs to turn Ras ‘off’ have been difficult because it’s part of difficult-to-drug molecular complexes. Thanks to new biophysical approaches, there are a few anti-Ras compounds in early-stage clinical trials and the field of targeting small G protein regulatory complexes has been rejuvenated. Join CHI’s Inaugural Small G Proteins conference to hear from drug discovery chemists, biologists, and pharmacologists working on ‘Ras’ and other small G protein-related projects.

Preliminary Agenda


Drugging KRAS and SOS1 with Small Molecules

Dirk Kessler, PhD, Scientific Director, New Therapeutic Concepts, Boehringer Ingelheim RCV, Austria

Talk Title to be Announced

Jill Hallin, MS, Principal Scientist, Drug Discovery, Mirati Therapeutics


Targeting KRAS Directly with Novel Drug Discovery Efforts at the NCI RAS Initiative

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research (FNLCR)

NON-Ras GTPases

Griptides: High-affinity Ras Binders that Remodel its Effector Domain

John McGee, PhD, Associate Director and Scientific Founder, FogPharma

The Rag GTPases in Nutrient Sensing and Regulation of mTORC1 Signaling

Roberto Zoncu, PhD, Co-Founder, Frontier Medicines; Professor, Biochemistry Division, Molecular and Cell Biology Department, University of California Berkeley

Small-Molecule Ral GTPase Covalent Inhibitors

Samy Meroueh, PhD, Associate Professor, Biochemistry & Molecular Biology, Indiana University


Blocking Receptor Tyrosine Kinase Signaling in Mutant KRAS Cells via Allosteric SHP2 Inhibitors

Huaixiang Hao, PhD, Novartis, Principal Scientist II, Oncology, Novartis Institutes for BioMedical Research


For more details on the conference, please contact:
Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286